Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
-
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving...
-
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a...
-
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater...
-
Santhera ernennt Marc Clausse zum Chief Commercial Officer, um die nächste Wachstumsphase voranzutreiben
-
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
-
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
-
CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
-
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
-
Markteinführung in der Schweiz für das zweite Halbjahr 2026 erwartet Pratteln, Schweiz, 15. Januar 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass die Schweizerische Heilmittelbehörde...